Tonix Pharmaceuticals Holding Corp Net Assets
Tonix Pharmaceuticals Holding Corp net assets. Based on the latest financial reports, Tonix Pharmaceuticals Holding Corp (TNXP) has net assets worth $245.15 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($277.17 Million) and total liabilities ($32.02 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore net asset growth rate of Tonix Pharmaceuticals Holding Corp to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $245.15 Million |
| % of Total Assets | 88.45% |
| Annual Growth Rate | 66.34% |
| 5-Year Change | 12.09% |
| 10-Year Change | 866.64% |
| Growth Volatility | 269.57 |
Net Assets of Tonix Pharmaceuticals Holding Corp (2008–2025)
Net assets of Tonix Pharmaceuticals Holding Corp from 2008 to 2025. This chart illustrates how Tonix Pharmaceuticals Holding Corp's net assets have evolved over time, based on quarterly financial data. See Tonix Pharmaceuticals Holding Corp balance sheet quality to measure how much of total assets are equity-financed.
Annual Net Assets for Tonix Pharmaceuticals Holding Corp (2008–2025)
The table below shows the annual net assets of Tonix Pharmaceuticals Holding Corp from 2008 to 2025. For live market cap and overall valuation, see Tonix Pharmaceuticals Holding Corp (TNXP) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $245.15 Million | +75.66% |
| 2024-12-31 | $139.56 Million | +32.25% |
| 2023-12-31 | $105.53 Million | -49.07% |
| 2022-12-31 | $207.18 Million | -5.27% |
| 2021-12-31 | $218.72 Million | +149.54% |
| 2020-12-31 | $87.65 Million | +830.74% |
| 2019-12-31 | $9.42 Million | -60.21% |
| 2018-12-31 | $23.66 Million | -3.87% |
| 2017-12-31 | $24.62 Million | -2.94% |
| 2016-12-31 | $25.36 Million | -37.01% |
| 2015-12-31 | $40.26 Million | +11.55% |
| 2014-12-31 | $36.09 Million | +454.24% |
| 2013-12-31 | $6.51 Million | +579.25% |
| 2012-12-31 | $958.71K | +139.07% |
| 2011-12-31 | $-2.45 Million | -43095.09% |
| 2010-12-31 | $-5.68K | -147.17% |
| 2009-12-31 | $12.04K | -71.93% |
| 2008-12-31 | $42.91K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Tonix Pharmaceuticals Holding Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 85469290900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Tonix Pharmaceuticals Holding Corp Net Assets Breakdown (December 2025)
Tonix Pharmaceuticals Holding Corp net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $13.00K | 0.01% |
| Other Comprehensive Income | $-289.00K | -0.12% |
| Other Components | $1.10 Billion | 448.76% |
| Total Equity | $245.15 Million | 100.00% |
Tonix Pharmaceuticals Holding Corp Competitors by Market Cap
The table below lists competitors of Tonix Pharmaceuticals Holding Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Eureka Acquisition Corp Unit
NASDAQ:EURKU
|
$72.60 Million |
|
Aemulus Holdings Bhd
KLSE:0181
|
$72.61 Million |
|
China Harmony Auto Holding Limited
F:HA5
|
$72.63 Million |
|
Talga Group Ltd
F:TGX
|
$72.63 Million |
|
Song Shang Electronics Co Ltd
TWO:6156
|
$72.56 Million |
|
Wilmar Cahaya Indonesia Tbk
JK:CEKA
|
$72.52 Million |
|
Melrose Industries PLC
LSE:MRO
|
$72.51 Million |
|
Hunya Foods Co Ltd
TW:1236
|
$72.50 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Tonix Pharmaceuticals Holding Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 139,558,000 to 245,150,000, a change of 105,592,000 (75.7%).
- Net loss of 124,021,000 reduced equity.
- Share repurchases of 13,760,000 reduced equity.
- New share issuances of 237,940,000 increased equity.
- Other comprehensive income decreased equity by 34,000.
- Other factors increased equity by 5,467,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-124.02 Million | -50.59% |
| Share Repurchases | $13.76 Million | -5.61% |
| Share Issuances | $237.94 Million | +97.06% |
| Other Comprehensive Income | $-34.00K | -0.01% |
| Other Changes | $5.47 Million | +2.23% |
| Total Change | $- | 75.66% |
Book Value vs Market Value Analysis
This analysis compares Tonix Pharmaceuticals Holding Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.18x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.00x to 0.18x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-12-31 | $4290900.00 | $5.11 | x |
| 2009-12-31 | $1204300.00 | $5.11 | x |
| 2010-12-31 | $-568100.00 | $5.11 | x |
| 2011-12-31 | $-245391300.00 | $5.11 | x |
| 2012-12-31 | $95870800.00 | $5.11 | x |
| 2013-12-31 | $651200000.00 | $5.11 | x |
| 2014-12-31 | $3609200000.00 | $5.11 | x |
| 2015-12-31 | $2013100000.00 | $5.11 | x |
| 2016-12-31 | $634025000.00 | $5.11 | x |
| 2017-12-31 | $246160000.00 | $5.11 | x |
| 2018-12-31 | $139200000.00 | $5.11 | x |
| 2019-12-31 | $3751792.83 | $5.11 | x |
| 2020-12-31 | $593017.59 | $5.11 | x |
| 2021-12-31 | $388595.34 | $5.11 | x |
| 2022-12-31 | $709357.35 | $5.11 | x |
| 2023-12-31 | $13315.46 | $5.11 | x |
| 2024-12-31 | $189.53 | $5.11 | x |
| 2025-12-31 | $28.80 | $5.11 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Tonix Pharmaceuticals Holding Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -50.59%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -946.22%
- • Asset Turnover: 0.05x
- • Equity Multiplier: 1.13x
- Recent ROE (-50.59%) is above the historical average (-96.09%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | -49.25% | 0.00% | 0.00x | 1.07x | $-25.42K |
| 2009 | -256.30% | 0.00% | 0.00x | 1.08x | $-32.07K |
| 2010 | 0.00% | 0.00% | 0.00x | 0.00x | $-17.16K |
| 2011 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.22 Million |
| 2012 | -0.99% | -504.00% | 0.00x | 2.21x | $-105.32K |
| 2013 | -167.14% | 0.00% | 0.00x | 1.34x | $-11.54 Million |
| 2014 | -76.52% | 0.00% | 0.00x | 1.10x | $-31.23 Million |
| 2015 | -119.35% | 0.00% | 0.00x | 1.17x | $-52.08 Million |
| 2016 | -153.16% | 0.00% | 0.00x | 1.08x | $-41.38 Million |
| 2017 | -85.81% | 0.00% | 0.00x | 1.09x | $-23.58 Million |
| 2018 | -110.25% | 0.00% | 0.00x | 1.11x | $-28.46 Million |
| 2019 | -301.39% | 0.00% | 0.00x | 1.55x | $-29.32 Million |
| 2020 | -57.49% | -1729.17% | 0.03x | 1.12x | $-59.15 Million |
| 2021 | -42.16% | 0.00% | 0.00x | 1.10x | $-114.08 Million |
| 2022 | -55.51% | -1274.00% | 0.04x | 1.09x | $-135.72 Million |
| 2023 | -110.55% | -1501.78% | 0.05x | 1.46x | $-127.21 Million |
| 2024 | -93.18% | -1288.25% | 0.06x | 1.17x | $-143.99 Million |
| 2025 | -50.59% | -946.22% | 0.05x | 1.13x | $-148.54 Million |
Industry Comparison
This section compares Tonix Pharmaceuticals Holding Corp's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $211,904,180
- Average return on equity (ROE) among peers: 1119.81%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Tonix Pharmaceuticals Holding Corp (TNXP) | $245.15 Million | -49.25% | 0.13x | $72.59 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $27.43 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $178.43 Million | -42.75% | 0.25x | $241.32 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $181.82 Million | -56.28% | 0.31x | $15.62 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $-41.16 Million | 0.00% | 0.00x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $155.53K | 11625.26% | 37.80x | $804.31 Million |
| ABVC Biopharma Inc (ABVC) | $35.27K | -72.00% | 1.50x | $26.65 Million |
| Abivax SA American Depositary Shares (ABVX) | $17.90 Million | -209.78% | 2.98x | $7.77 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $699.13 Million | -33.65% | 0.12x | $3.70 Billion |
About Tonix Pharmaceuticals Holding Corp
Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia. It also markets Zembrace SymTouch and T… Read more